Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study

(2020) Erika J Lampert et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

(2020) Dmitriy Zamarin et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

(2020) Chang Yang et al.   Frontiers in Immunology

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study

(2019) U A Matulonis et al.   ANNALS OF ONCOLOGY

Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

(2019) E. Pujade-Lauraine et al.   GYNECOLOGIC ONCOLOGY

992OFORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

(2019) K Moore et al.   ANNALS OF ONCOLOGY

Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design

(2018) Eric Pujade-Lauraine et al.   Future Oncology

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer

(2018) Kathleen N Moore et al.   Future Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

(2018) Panagiotis A. Konstantinopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

(2018) Bin Zhao et al.   Journal for ImmunoTherapy of Cancer

Clinical statistics of gynecologic cancers in Japan

(2017) Wataru Yamagami et al.   Journal of Gynecologic Oncology

Ovarian cancer stem cells more questions than answers

(2017) Petronella Beatrix Ottevanger   SEMINARS IN CANCER BIOLOGY

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA–Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)

(2016) Christian Kurzeder et al.   JOURNAL OF CLINICAL ONCOLOGY

Ovarian cancer

(2016) Ursula A. Matulonis et al.   Nature Reviews Disease Primers

Targeting Programmed Cell Death 1 in Ovarian Cancer

(2015) Krisztian Homicsko et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

(2014) Daniela Luvero et al.   Therapeutic Advances in Medical Oncology

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) J. A. Ledermann et al.   ANNALS OF ONCOLOGY

Optimal first-line treatment in ovarian cancer

(2012) F. A. Raja et al.   ANNALS OF ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE